Clinical Trials Logo

Secondary Hyperparathyroidism clinical trials

View clinical trials related to Secondary Hyperparathyroidism.

Filter by:

NCT ID: NCT00664430 Terminated - Clinical trials for Secondary Hyperparathyroidism

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Start date: January 2009
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate the efficacy and safety of paricalcitol in participants with moderate to severe secondary hyperparathyroidism (SHPT) undergoing hemodialysis who are resistant to treatment with calcitriol.

NCT ID: NCT00601328 Completed - Clinical trials for Secondary Hyperparathyroidism

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions

Start date: July 2003
Phase: N/A
Study type: Interventional

The objective of this study was to assess the bioequivalence of Roxane Laboratories' Calcitriol capsules, 0.25 mcg, to ROCALTROL® capsules, 0.25 mcg (Roche) using a single-dose, 2-treatment, 2-period, crossover design, under fasting conditions

NCT ID: NCT00560300 Completed - Clinical trials for Secondary Hyperparathyroidism

Regulation of Bone Formation in Renal Osteodystrophy

Start date: November 2000
Phase: Phase 2
Study type: Interventional

To examine the effects of two types of active vitamin D (calcitriol and doxercalciferol) and two phosphate binders (sevelamer and calcium carbonate) on the bone disease and blood tests of children with kidney failure

NCT ID: NCT00537979 Completed - Clinical trials for Secondary Hyperparathyroidism

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

Start date: September 2007
Phase: Phase 4
Study type: Interventional

Prospective, non-randomized, multi-center study to assess the efficacy and safety of paricalcitol injection or oral administered over 6 months to patients with secondary hyperparathyroidism on dialysis.

NCT ID: NCT00469599 Terminated - Clinical trials for Chronic Kidney Disease

Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Start date: July 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to compare alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.

NCT ID: NCT00463021 Completed - Clinical trials for Secondary Hyperparathyroidism

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Start date: April 2007
Phase: Phase 4
Study type: Interventional

Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.

NCT ID: NCT00454350 Completed - Clinical trials for Secondary Hyperparathyroidism

A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

Start date: February 2007
Phase: Phase 4
Study type: Interventional

This study will measure serum levels of the active Vitamin D compound that circulates in hemodialysis subjects treated with either doxercalciferol injection (Hectorol®) or Zemplar® (paricalcitol injection).

NCT ID: NCT00446329 Terminated - Clinical trials for Secondary Hyperparathyroidism

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Start date: July 2006
Phase: Phase 4
Study type: Interventional

The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.

NCT ID: NCT00431496 Completed - Anemia Clinical Trials

A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to show that the use of cinacalcet in patients with End Stage Renal Disease can help achieve NKF K/DOQI targets for both serum calcium and calcium phosphorous product.

NCT ID: NCT00418600 Completed - Clinical trials for Secondary Hyperparathyroidism

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

Start date: November 2006
Phase: Phase 4
Study type: Interventional

Hectorol is a safe and effective treatment of secondary hyperparathyroidism in hemodialysis patients. Hectorol (doxercalciferol capsules) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and in pre-dialysis patients with Stage 3 or Stage 4 chronic kidney disease. Hectorol (doxercalciferol injection) is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. This protocol will determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting subject from Hectorol (doxercalciferol injection.) The study will enroll hemodialysis patients that have been controlled on intravenous Hectorol. the information gained from this study will be a useful guide for physicians in managing CKD Stage 5 patients for whom a change from intravenous to oral vitamin D administration is appropriate.